HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose

Files in This Item:
64_EJ16-0546.pdf846.87 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/68414

Title: Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose
Authors: Nomoto, Hiroshi Browse this author
Kimachi, Kimihiko Browse this author
Miyoshi, Hideaki Browse this author →KAKEN DB
Kameda, Hiraku Browse this author
Cho, Kyu Yong Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Nagai, So Browse this author →KAKEN DB
Kondo, Takuma Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Keywords: Blood glucose fluctuation
DPP-4 inhibitors
Type 2 diabetes mellitus
Issue Date: Apr-2017
Publisher: The Japan Endocrine Society
Journal Title: Endocrine Journal
Volume: 64
Issue: 4
Start Page: 417
End Page: 424
Publisher DOI: 10.1507/endocrj.EJ16-0546
PMID: 28260702
Abstract: To date, several clinical trials have compared differences in glucose fluctuation observed with dipeptidyl peptidase-4 inhibitor treatment in patients with type 2 diabetes mellitus. However, most patients were assessed for limited periods or during hospitalization. The aim of the present study was to evaluate the effects of switching from sitagliptin to vildagliptin, or vice versa, on 12-week glucose fluctuations using self-monitoring of blood glucose in the standard care setting. We conducted a multicenter, prospective, open-label controlled trial in Japanese patients with type 2 diabetes. Thirty-two patients were treated with vildagliptin (50 mg) twice daily or sitagliptin (50 mg) once daily and were allocated to one of two groups: vildagliptin treatment for 12 weeks before switching to sitagliptin for 12 weeks, or vice versa. Daily profiles of blood glucose were assessed several times during each treatment period, and the mean amplitude of glycemic excursions and M-value were calculated. Metabolic biomarkers such as hemoglobin A1c (HbA1c), glycated albumin, and 1,5-anhydroglucitol were also assessed. With vildagliptin treatment, mean amplitude of glycemic excursions was significantly improved compared with sitagliptin treatment (57.9 ± 22.2 vs. 68.9 ± 33.0 mg/dL; p=0.0045). M-value (p=0.019) and mean blood glucose (p=0.0021) were also lower with vildagliptin, as were HbA1c, glycated albumin, and 1,5-anhydroglucitol. There were no significant differences in other metabolic parameters evaluated. Reduction of daily blood glucose profile fluctuations by vildagliptin was superior to that of sitagliptin in Japanese patients with type 2 diabetes.
Type: article
URI: http://hdl.handle.net/2115/68414
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University